Comparative Pharmacology
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus TAVIST 1.
EPINASTINE HYDROCHLORIDE vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist. Inhibits histamine release from mast cells and basophils, and reduces chemotaxis and activation of eosinophils. Also suppresses cytokine production from T lymphocytes.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
For allergic rhinitis and urticaria: 10 mg twice daily orally (20 mg/day). For ophthalmic use: 1 drop in affected eye(s) twice daily of 0.05% solution.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 5.7 to 9.2 hours in healthy adults. In elderly patients, the half-life may be prolonged due to reduced renal function. The half-life supports twice-daily dosing for most indications.
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Renal excretion accounts for approximately 39% of the administered dose, with about 28% as unchanged drug and 11% as metabolites. Fecal excretion is minimal at approximately 10%. Biliary excretion is not a significant route. Overall, renal clearance is the primary elimination pathway.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category A/B
Category C
Antihistamine
Antihistamine